上述"调研清单"清晰地勾勒出当前外资在A股市场的关注焦点，即以AI为代表的科技和医药两大赛道。 高盛在近日发布的报告中表示，DeepSeek-R1的发布在2025年引发了中国科技公司的强劲反弹。从基本 面来看，高盛估计，未来十年，通过节约成本、提高生产率和创造新的收入机会，AI的广泛应用有望 推动企业盈利每年增长3%。 2025年以来，近800家外资机构合计调研A股上市公司近万次。其中，Point 72资产管理公司以263次调 研位居榜首；高盛、美银证券等国际大行的调研次数也均超过百次。从调研方向来看，科技和医药是外 资机构最为关注的两大赛道。 年内外资调研A股近万次 数据显示，截至12月26日，今年以来共有798家外资机构现身A股上市公司调研名单，合计调研9308 次。 具体来看，被称为"华尔街最疯狂赚钱机器"的Point 72资产管理公司今年以来调研A股上市公司263次， 排名首位。在2023和2024年，Point 72资产管理公司全年分别调研A股上市公司255次、259次，均为当 年外资调研榜第一位，堪称"A股调研劳模"。此外，高盛、美银证券、花旗环球等机构今年以来的调研 次数均超过100次。 从调研 ...

Investment Rating - The report suggests a positive investment outlook for the medical device sector, particularly in brain-computer interface devices, which are expected to see accelerated commercialization due to supportive policies [1][3]. Core Insights - Recent policies have significantly increased support for innovation in medical devices, with the National Medical Products Administration actively promoting faster market entry for brain-computer interface devices, indicating a diverse application landscape and substantial future potential [1][3]. - The pharmaceutical sector is witnessing positive developments, such as GSK's approval of mepolizumab for a new indication in COPD patients, marking it as the first monthly administered biologic in China, which is expected to reduce the annual incidence of severe exacerbations significantly [1][32]. - The report highlights the approval of Wegovy® tablets in the U.S. for weight management, emphasizing its potential impact on the market as the first oral GLP-1 receptor agonist for this purpose [37][40]. Summary by Sections Pharmaceutical Sector - Mepolizumab has been approved for COPD treatment in China, with a monthly dosing schedule, targeting a significant patient population [1][32]. - The A/H share innovation drug sector maintains high activity levels, with new drug approvals and cross-border transactions remaining robust [16][28]. Biologics - Wegovy® tablets have been approved in the U.S. for weight management, showing similar weight loss efficacy to its injectable counterpart, with a significant portion of participants achieving substantial weight loss [37][40]. CXO and Pharmaceutical Supply Chain - The CXO sector continues to show upward momentum, supported by a stable order backlog, with November financing levels slightly above the annual average [44][46]. Medical Devices - The centralized procurement process for high-value medical consumables is progressing steadily, with high selection rates in multiple rounds of bidding, indicating a favorable environment for leading domestic companies [2][52]. Retail Pharmacy - The industry is undergoing a consolidation phase, with leading companies expected to benefit from increased market share through mergers and acquisitions [2][3]. Medical Services and Consumer Healthcare - Aier Eye Hospital's acquisition of 39 institutions for 960 million yuan strengthens its market position, with the acquired entities showing signs of financial recovery [2][3].

Investment Rating - The report indicates a positive outlook for the SMO industry, suggesting it is entering a new growth cycle [15]. Core Insights - The SMO industry is experiencing steady growth driven by an increase in clinical trial registrations, particularly for innovative drugs, with a projected market size of 35 billion yuan by 2030 [23]. - The report highlights the recovery of the innovative drug sector, with an emphasis on the importance of quality over quantity in drug development [9]. - The medical device sector is benefiting from a rebound in bidding activities and government subsidies for home medical devices, indicating a favorable investment environment [56]. Summary by Sections Market Review - The report notes a slight decline in the CITIC pharmaceutical index, underperforming the CSI 300 index by 2.14 percentage points, ranking 26th among 30 primary industries [6]. Industry and Stock Events - The report identifies key stocks that have performed well, including Hongyuan Pharmaceutical and Luyan Pharmaceutical, while also noting significant declines in stocks like ST Bailing and Huaren Health [6]. Overall Viewpoint and Investment Themes - The report emphasizes the transition in the innovative drug sector from quantity to quality, recommending companies such as BeiGene and Innovent Biologics for their potential to deliver profits [9]. - In the medical device sector, the report highlights the recovery in imaging equipment procurement and the growth of home medical devices, recommending companies like Mindray and Yuyue Medical [9]. - The report discusses the potential for the CXO and life sciences services sector to recover, with a focus on companies that can leverage their market position for high-profit returns [9]. - The report suggests that the pharmaceutical industry is entering a new growth cycle, particularly in the specialty raw materials sector, with companies like Tonghua Dongbao and Huahai Pharmaceutical recommended for investment [9]. SMO Industry Insights - The SMO industry is characterized by a stable growth trajectory, with a significant increase in clinical trial registrations, particularly in complex therapeutic areas [23]. - The report notes that the demand for SMO services is expected to rise as the number of innovative drug trials increases, with a forecasted annual registration of 4,900 clinical trials in 2024, representing a 13.9% year-on-year growth [23]. - The report highlights the potential for AI applications to enhance efficiency and reduce costs in the SMO sector, which traditionally relies heavily on manual processes [33]. Medical Services and Pharmacy - The report expresses optimism about the pharmacy sector, driven by the acceleration of prescription outflow and the optimization of competitive dynamics, recommending companies like YaoXing and YiFeng Pharmacy [61]. - In the medical services sector, the report highlights the potential for private healthcare providers to enhance their competitive edge through reforms and the expansion of commercial insurance [63].

Core Viewpoint - The investment accounts managed by the company have shown a mixed performance this year, with a total profit of 1.9 million yuan, down from a peak of 2.3 million yuan earlier in the year, indicating a drawdown of 400,000 yuan [2][3]. Group 1: Account Performance - The total assets in the on-market ETF account amount to 2.6 million yuan, while the off-market fund account holds 5.4 million yuan, and the advisory portfolio has 1.2 million yuan [7]. - The on-market ETF account has a year-to-date profit of 460,000 yuan, with a current yield of 40.19% [5][6]. - The off-market fund account has a year-to-date profit of 1.338 million yuan, with a yield of 34.21% [15][16]. Group 2: Investment Strategy - The company has shifted its strategy by reducing its position in a value ETF by 100,000 yuan and reallocating that amount to the Hang Seng Consumer ETF, which has seen a decrease in floating profit from 11% to 8% [4]. - The rationale for this shift includes the belief that consumer valuations are at historical lows and that there will likely be consumption stimulus policies next year, which could improve industry sentiment [5]. - The core holdings in the on-market ETF account focus on Hong Kong stocks, with significant investments in sectors such as innovative pharmaceuticals, technology, and consumer goods [8][9]. Group 3: Market Trends - The recent downturn in the Hong Kong stock market has not changed the company's long-term investment logic, which emphasizes the valuation advantages of Hong Kong stocks compared to A-shares [10]. - The company has noted that the recent performance of aerospace and satellite ETFs has been strong, contributing significantly to this week's profits [11]. - The company adheres to a philosophy of avoiding high-risk investments and focusing on undervalued sectors for long-term gains [12]. Group 4: Precious Metals Market - The precious metals market has experienced significant price increases, with platinum prices rising over 172% year-to-date, driven by demand from the aerospace sector [24]. - The company had previously identified platinum as a valuable investment but missed the opportunity to invest heavily at lower prices [21][24]. - The company advises against chasing prices in the current market, emphasizing the importance of strategic investment rather than following trends [25].

Group 1 - The recent recruitment of prominent analysts in the pharmaceutical, banking, and overseas research sectors indicates a strategic focus on these key areas for the research institute [2] - Zhang Jinyang's team, known for its expertise in innovative drugs, has received multiple awards from 2016 to 2025, including the Golden Bull Award and the Crystal Ball Award, and is recognized for accurately predicting market trends [2] - Wang Xianshuang's team has also achieved significant accolades in the financial sector, including being ranked first in both the Golden Bull Award and the Crystal Ball Award from 2019 to 2024, showcasing their strong analytical capabilities [2] Group 2 - Guolian Minsheng is positioned as a benchmark for industry consolidation, with a research institute led by top analysts, creating a comprehensive and forward-looking research system [3] - The integration of "New Fortune-level" teams across core sectors aims to enhance the research capabilities and foster innovation within the organization [3] - The platform's upgrade allows star analysts to leverage their expertise and drive growth, attracting top-tier teams to join [3]

Core Insights - The "2025 Financial Annual Conference" held in Beijing focused on high-quality development of listed companies, emphasizing resilience and growth through cycles, with participation from over 200 listed companies and various industry leaders [1] Group 1: Industry Trends - The innovation drug sector is currently experiencing a critical period for breakthroughs, with significant investments in technology and resources, despite facing a temporary downturn from 2023 to 2024 [4][5] - The competition in the PD1/PDL1 market has drastically reduced treatment costs from 1 million RMB to 30,000-50,000 RMB, enhancing accessibility to quality medical resources [4] Group 2: Company Insights - Sihruidi Pharmaceutical, which specializes in innovative oncology drugs, has achieved nearly 2 billion RMB in sales from its first subcutaneous PDL1 product over four years and is expanding into nuclear medicine and mRNA therapies [2][4] - The company emphasizes the importance of strategic partnerships for successful market entry, citing a collaboration with Xiansheng Pharmaceutical that led to 567 million RMB in sales in its first full fiscal year [5] Group 3: Challenges in the Industry - The innovation drug industry faces two main challenges: securing capital for long-term drug development, which can take over ten years, and establishing effective sales channels post-launch [5][6] - Domestic pharmaceutical companies often struggle with smaller collaboration deals compared to multinational corporations, indicating a gap in industry strength [6]

Core Insights - The article highlights the resurgence of the innovative drug sector in China, marking 2025 as a pivotal year for medical innovation, with significant investment activity and market performance [2][6] - The investment strategy of Qiming Venture Partners, focusing on innovative drugs and medical devices, has proven successful, with a notable increase in IPOs and market valuations in the sector [3][7] Investment Trends - In 2025, Qiming Venture Partners invested in over 30 projects in the medical innovation field, contributing more than 30 billion RMB, with some investments made in late 2024 [3][6] - The company has been particularly active in supporting innovative surgical robotics, exemplified by its early investment in Cornerstone Robotics, which has raised over 3 billion RMB [3][4] Market Dynamics - The medical sector experienced a downturn in 2021, leading to cautious investment behavior among many firms; however, Qiming maintained close industry engagement during this period [6][7] - By mid-2024, Qiming's strategy of investing in undervalued Chinese innovations began to yield positive results, coinciding with a broader market recovery [7][8] Global Recognition - In 2025, approximately 40% of new drug projects licensed in by global pharmaceutical companies originated from Chinese biotech firms, a significant increase from 0% in 2019 [9][10] - The article emphasizes the growing global influence of Chinese medical innovations, with successful business development (BD) transactions indicating the capability of Chinese firms to collaborate with leading global pharmaceutical companies [10][11] Future Outlook - The article suggests that the next phase of medical investment will focus on building a sustainable ecosystem for biopharmaceuticals, with an emphasis on global market participation [8][12] - Qiming Venture Partners aims to assist its portfolio companies in navigating global markets, having facilitated numerous BD transactions totaling 19.7 billion USD by October 2025 [11][12]

Core Insights - The article emphasizes the collective intelligence of investors, highlighting that the "Top Ten Core Asset Portfolio" launched by the company in 2019 has achieved a cumulative return of 274.61% by December 15, significantly outperforming the Shanghai and Shenzhen 300 Index and the Hang Seng Index [1] - In 2023, the company launched another portfolio called "Global Vision: Betting on China," which has recorded a 15.16% increase in 2024, outperforming the Wind All A Index by 5.16% [1] - As of December 26, 2025, the "Global Vision: Betting on China" portfolio has achieved a 29.72% increase, surpassing the Shanghai and Shenzhen 300 Index by 11.36 percentage points [1] ETF Performance Summary - The A500 ETF Fund (512050.SH) recorded a 25.58% increase in 2025 [2] - The ChiNext 50 ETF (159949.SZ) saw a remarkable increase of 60.67% [2] - The Hong Kong Innovation Drug ETF (513120) led the performance with a 71.86% increase [2] - The Semiconductor Theme ETF (588200.SH) experienced a decline of 59.15% [2] - The Internet Theme ETF (159792.SZ) increased by 24.033% [2] - The H-share ETF (510900.SH) rose by 21.58% [2] - The Consumption ETF (159928.SZ) decreased by 2.08% [2] - The Broker ETF (512000.SH) increased by 5.00% [2] - The S&P 500 ETF (513500.SH) recorded a 13.83% increase [2] Industry Highlights - The pharmaceutical sector has transformed from one of the worst-performing sectors to one of the strongest, with innovative drug companies frequently achieving record-breaking sales [3] - The total transaction volume for innovative drug license-out deals is expected to exceed $100 billion, accounting for nearly half of the global pharmaceutical business development transaction volume [4] - The Hong Kong Innovation Drug ETF (513120) tracks the China Hong Kong Innovation Drug Index, focusing on high-quality biotech companies in the Hong Kong market [4] - The ETF has a current scale of 24.1 billion yuan, with an average daily trading volume exceeding 5.3 billion yuan, making it the largest and most liquid thematic index fund in the market [4] - The ChiNext 50 ETF (159949) has also performed well, with a year-to-date increase of 59.86% and a significant increase of 129.61% since the "924" period [5][7] Market Trends - The ChiNext 50 Index employs a unique "liquidity-first, scale-second" strategy, selecting the 50 largest and most liquid stocks from the ChiNext 100, representing the core strengths of the ChiNext market [9] - The ETF's performance benefits from the dual advantages of leading stocks and sector rotation, particularly in the information technology and new energy sectors [9] - Looking ahead to 2026, the market is expected to benefit from continued overseas liquidity easing and domestic policies aimed at expanding domestic demand, which may improve the corporate profit environment [10]

Core Viewpoint - The recent surge in new stock listings in the A-share market, particularly with companies like Moer Thread and Muxi Co., has significantly boosted investor enthusiasm for new stock subscriptions [1][12]. Group 1: New Stock Subscription Data - The number of online subscriptions for new stocks on the Sci-Tech Innovation Board has reached nearly 670,000 households, setting a historical high [2]. - The main board has seen over 16.5 million households participating in online subscriptions, an increase of nearly 10 million households in just over a year, breaking records since early 2022 [2]. - The number of online subscriptions for the ChiNext board is close to 14 million households, returning to levels seen at the end of 2021 [2][6]. Group 2: New Stock Performance - The online issuance of Shuangxin Environmental attracted 16.55 million investor subscriptions, with a total effective subscription amount reaching 335.23 billion shares, setting a new record for the main board in 2022 [4]. - Moer Thread's stock opened at a 468.78% increase on its first day, reaching a peak price of 941.08 yuan per share, allowing investors to earn over 410,000 yuan per subscription [12]. - Muxi Co. also saw a first-day opening increase of 568.83%, with a peak price of 895 yuan per share, yielding nearly 400,000 yuan per subscription for investors [12]. Group 3: Market Trends and Investor Behavior - The influx of investors into the new stock subscription market has led to increased competition, resulting in a decline in the new stock winning rate [2][13]. - Despite the current market recovery, the probability of new stocks breaking below their issue price is low, but investors are advised to enhance their understanding of the fundamentals of new stocks to avoid unnecessary risks [2][13]. - The overall market activity has increased, with A-share market transactions exceeding 2 trillion yuan, and the Shanghai Composite Index showing a nearly 2% increase in December [15].

Group 1 - The core theme of the investment strategy meeting held by Fangzheng Fubang Fund is "Transformational Innovation," focusing on investment opportunities and challenges for the year 2026 [1] - In 2025, the A-share market exhibited a structural market trend, with new technology sectors, particularly those related to AI, performing strongly, while traditional economic sectors remained sluggish [1][2] - The difficulty of further valuation increases in the A-share market is expected to rise, prompting a focus on industries capable of profit enhancement, especially those that have been at the bottom in terms of profit, valuation, and stock price over the past two years [1][2] Group 2 - Key sectors for potential investment include new energy, chemicals, building materials, and the innovative pharmaceutical industry, with new energy transitioning to a collaborative development phase of "generation-storage-usage" [2] - Breakthroughs in energy storage technology and cost reductions are expected to unlock diverse market opportunities, allowing companies with technological and integration advantages to evolve from equipment suppliers to energy solution providers [2] - The innovative pharmaceutical sector is anticipated to increase R&D investment after securing cash flow through business development and public offerings, while certain chemical and building material industries are set to benefit from "anti-involution" policies and are entering a recovery phase [2]